An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
XILIO-XTX301-01-02-001Phase IOPEN TO ACCRUAL
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors